OP52 Parathyroid hormone and 25(OH) vitamin D levels in Cameroonian patients with chronic kidney disease: a comparison of diabetic and non-diabetic patients

resistant hypertension. The current study evaluated the efficacy of this therapy among diabetic patients. Methods: Among 672 diabetic patients who consecutively consulted in Yaounde Central Hospital, 292 (56%) were hypertensive and 63 presented resistant hypertension. Seventeen patients who met the inclusion criteria were prospectively included in the trial. These criteria were as follows: hypertension of ≥6 months without any apparent cause; clinical BP measurement ≥140/90 mmHg and self blood pressure measurement (SBPM) ≥130/85 mmHg with at least three antihypertensive drugs (including a diuretic) and no renal insufficiency. Randomized controlled single blinded trial was done. Nine patients received 25 mg/day of spironolactone and the rest (8) were put on another alternative, all added to their previous regimen. Baseline serum potassium and creatinine levels were checked and controls were done during treatment. Results: Low-dose spironolactone was associated with an additional significant mean decrease in systolic BP of −33 vs −14 mmHg (P<0.001), and in diastolic BP of −14 vs −5 mmHg (P<0.001) in SBPM. After 1 month of spironolactone, all the patients were controlled under 130/80 mmHg with significant clinical BP reduction of 158±17/86±11 mmHg to 125±11/72±8 mmHg, vs 158±8/94±8 mmHg to 144±17/89±12 mmHg in the control group. There was no significant variation in serum potassium and creatinine levels in both groups. Conclusion: Resistant hypertension is frequent among diabetics and addition of spironolactone constitutes an alternative.